Levosimendan: Calcium sensitizer and inodilator

Anesthesiology Clinics

Volumn 28, Issue 4, 2010, Pages 753-760

  Milligan, Daun Johnson ^a   Fields, Aaron M ^a,b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Calcium sensitizer; Decompensated heart failure; Inodilators; Levosimendan

Indexed keywords

ADENOSINE TRIPHOSPHATE; CATECHOLAMINE; DOBUTAMINE; HYPERTENSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INOTROPIC AGENT; LEVOSIMENDAN; NITRIC OXIDE; ROLIPRAM; SIGUAZODAN; TROPONIN C; TROPONIN I;

ACUTE HEART FAILURE; ANTIINFLAMMATORY ACTIVITY; CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DIASTOLE; DOSE RESPONSE; DRUG EFFICACY; HEADACHE; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PRELOAD; HEART PROTECTION; HEART STROKE VOLUME; HUMAN; HYPOKALEMIA; HYPOTENSION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SYSTEMIC VASCULAR RESISTANCE; SYSTOLE; VENOUS STASIS;

ANIMALS; CALCIUM; CARDIOPULMONARY BYPASS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYDRAZONES; NITRIC OXIDE; PYRIDAZINES; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 78149490340     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2010.08.003     Document Type: Review

References (20)

1. Bergh C.H., Bert A., Dahlstrom U., et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients in beta-blockers. Eur J Heart Fail 2010, 12:404-410.
2. Mills R.M., Hobbs R.E. Drug treatment of patients with decompensated heart failure. Am J Cardiovasc Drugs 2001, 1(2):119-125.
3. Follath F., Cleland J.G., Just H., et al. Steering committee and investigators of the levosimendan infusion versus dobutamine (LIDO) study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a random double-blind trial. Lancet 2002, 360:196-202.
4. Zairis MN, Apostolatos C, Anastasiadis P, et al. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO) [abstract 835-6]. Program and abstracts from the American College of Cardiology Annual Scientific Sessions 2004. New Orleans, LA, March 7-10, 2004.
5. Cleland J.G., Freemantle N., Coletta A., et al. Clinical trials update from the American heart association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006, 8(1):105-110.
6. Landoni G., Mizzi A., Biondi-Zoccai G., et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol 2010, 76:276-286.
7. Mebazaa A., Nieminen M.S., Filipattos G., et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009, 11:304-311.
8. Bergh C.H., Andersson B., Dahlstrom U., et al. Intravenous levosimendan versus dobutamine in acute decompensated heart failure patients treated with beta-blockers (BEAT-CHF study). Eur Heart J 2007, 28:5388-5389.
9. Uriate-Rodriguez A., Santa-Cabrera L., Sanchez-Palacios M., et al. Levosimendan use in the emergency management of decompensated peripartum cardiomyopathy. J Emerg Trauma Shock 2010, 3(1):94.
10. De Witt B.J., Ibrahim I.N., Bayer E., et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002, 94:1427-1433.
11. Sareila O., Korhonen R., Auvinen H., et al. Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. Br J Pharmacol 2008, 155:884-895.
12. Grossini C., Molinari C., Caimmi P., et al. Levosimendan induces NO production through p38 MAPK, ERK, and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009, 156:250-261.
13. van Hees H.W., Dekhuijzen P.N., Heunks L.M., et al. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:41-47.
14. Kurola J., Leppikangas H., Magga J., et al. Effect of levosimendan in experimental verapamil-induced myocardial depression. Scand J Trauma Resusc Emerg Med 2010, 18:12-19.
15. Siirila-Waris K., Suojaranta-Ylinen R., Harjola V.P., et al. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005, 19(3):345-349.
16. Tritapepe L., De Santis V., Vitale D., et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth 2006, 96(6):694-700.
17. Braun J.P., Jasulaitis D., Moshirzadeh M., et al. Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Crit Care 2006, 10:R17.
18. Duman D., Palit F., Simsek E., et al. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Can J Cardiol 2009, 25(10):e353-e356.
19. ISPUB. Dobutamine kills goods hearts! Levosimendan may not. Available at: Accessed April 3, 2010. http://www.ispub.com.
20. Levosimendan (INN)- drug information from Medic8.com Available at:, Accessed April 10, 2010. http://www.medic8.com/medicines/Levosimendan.html.